M·CAM releases Patently Obvious® on How Attractive is Chimerix

Date:  Wed, 2015-06-10

M·CAM releases Patently Obvious® on How Attractive is Chimerix

While Chimerix’s fully owned patent portfolio is fairly small, a number of licensing agreements have allowed the company to develop beyond its own proprietary technology. Combining in-house and licensed patents gives Chimerix a strong exclusivity position if its CMX001 and CMX157 candidates pass through clinical trials. With no glaring prior art problems and strong third-party interest in its technology, the market may be overweighting Chimerix’s IP risk. M·CAM believes the company’s IP risk is lower than industry average, which should allow for a clean product launch and make Chimerix an attractive acquisition target for Gilead, Novartis, and other large pharma players.

M·CAM’s Patently Obvious® is a report providing visibility into potentially unconsidered alternatives, including art in the public domain, to patent holdings across a variety of technology areas.

M·CAM is a global, full-service intellectual property and rights (IP&R) and intangible asset financial services firm. We provide the technical and financial systems that allow public and private markets to use IP&R and IA for regulated transactions in banking, securities, insurance, and public innovation investment and technology procurement. From our pioneering work in creating the world’s first standards-based innovation collateralization financial products for banking and securities to our work in grassroots innovator enablement and patent quality assurance programs, M·CAM provides the mechanism to balance the interests of public and commercial sectors to support and build thriving economies.

The M·CAM Patently Obvious® on How Attractive is Chimerix can be found HERE